Ovarian cancer is characterized by its insidious nature and high mortality rate, with 70% of patients diagnosed at an advanced stage (5-year survival rate<30%), and BRCA1/2 mutation carriers facing a lifetime risk of 44%-17% (41, 42). This evidence concerns the gene BRCA1 and ovarian cancer.